SecBot SecBot
8-K ·Filed Jun 17, 2026

CNMD

CONMED Corp
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago SEC0002077096-26-000203
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

Routine CFO appointment with no financial guidance or operational changes. The $3.8M equity grant (including $1.5M make-whole RSUs) represents modest dilution but is standard for a new hire. Monitor for any strategic shifts under new CFO, but near-term impact is minimal.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
CNMD ▲ +42.36% at T+60d
NEUTRAL call +42.36% · α vs SPY +40.46% · entry $32.58 → $46.38
Entry = T+0 close
Jun 17, 2026
via day close
T+1d
-0.12%
call -0.12% · α +0.19%
$32.54
settled 4mo ago
T+5d
+6.08%
call +6.08% · α +7.74%
$34.56
settled 4mo ago
T+20d
+38.15%
call +38.15% · α +37.62%
$45.01
settled 3mo ago
T+60d
+42.36%
call +42.36% · α +40.46%
$46.38
settled 6w ago

Price Chart

Loading chart...

Executive Summary

CONMED Corp announced the appointment of John E. Gallagher as CFO, effective July 15, 2026, with a compensation package including a $650,000 base salary, 85% target bonus, and $3.8M in equity grants. The outgoing CFO Todd Garner remains in an advisory capacity through November 2, 2026. This is a routine CFO succession filing with no material financial data.

Key Facts

  • John E. Gallagher appointed EVP, CFO effective July 15, 2026
  • Annual base salary of $650,000
  • Target annual bonus of 85% of base salary
  • Equity grant value of $2,300,000 (50% RSUs, 25% PSUs, 25% options)
  • Make-whole RSU grant of $1,500,000
  • One-time cash bonus of $34,750 if employed through Dec 31, 2026
  • Outgoing CFO Todd Garner remains in advisory capacity through Nov 2, 2026

Financial Impact

Total new CFO compensation package valued at approximately $4.5M (salary + target bonus + equity grants + make-whole + one-time bonus)

executive compensationequity dilution

Risk Factors

  • No financial data or guidance provided in filing
  • New CFO's prior experience at Certara and Cue Health may not directly translate to CONMED's surgical device business

Market Snapshot

Exchange
NYSE
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
0% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0002077096-26-000203
Document: ea0295016-8k_conmed.htm0002077096-26-000203
Document: ea029501601ex99-1.htm0002077096-26-000203
Document: 0002077096-26-000203-index-headers.html0002077096-26-000203
Document: 0002077096-26-000203-index.html0002077096-26-000203
Document: 0002077096-26-000203.txt0002077096-26-000203
4 reports for CNMD
Performance horizon
Filters
Rows
Reports for CNMD — sortable, filterable
TypeNow
Jun 17, 2026
18w ago
8-K
NEUTRAL ★ 3/10
$32.58 $45.01▲ +38.15%▲ +37.62%$47.20 (+44.87%)
Jun 1, 2026
21w ago
8-K
MIXED ★ 6/10
$34.65 $32.73▼ −5.54%▼ −4.24%$47.20 (+36.22%)
May 20, 2026
22w ago
8-K
NEUTRAL ★ 3/10
$37.01 $32.58▼ −11.97%▼ −12.71%$47.20 (+27.53%)
Apr 7, 2026
29w ago
DEFA14A
NEUTRAL ★ 3/10
$34.54 $35.88▲ +3.88%▼ −5.90%$47.20 (+36.65%)
Showing 4 of 4

US Market Status

Market Closed — Opens Thu (10h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 17, 2026